Aytu: Natesto prescription growth jumps in January

Wednesday February 21, 2018 0 comments Tags: Englewood, Aytu BioScience, Natesto, Josh Disbrow

ENGLEWOOD -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, announced prescription growth of Natesto in the U.S. in January was 300 percent higher than the same month in 2017.Aytu_logoUSE

Additionally, for the three months ending Jan. 31, 2018, Aytu said Natesto prescriptions increased 12% over the three-month period ending Oct. 31, 2017.

"Aytu is increasing adoption of Natesto at a rapid rate, and the Company is pleased with the sustained positive acceptance by physicians and patients,” said Josh Disbrow, Aytu’s CEO.

 The dual strengths of a highly differentiated product profile and a sales force becoming progressively more experienced at selling the product, has resulted in all-time highs for Natesto in terms of both prescription levels and prescribers.

“We remain enthusiastic about the uptake of Natesto, particularly the robust increase over these past 90 days. With the February 2018 launch of the Natesto Support Program, a new initiative aimed at increasing both new and refill prescription rates at retail pharmacies, we expect to further accelerate the growth of Natesto."

Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

Aytu currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T") and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging.

Aytu is also developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress.

MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA.